CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval of … | News

OXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) — Cure Pharmaceutical (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, and Milagro Pharmaceuticals, which seeks first-mover advantage in target health and wellness markets through key collaborations, today announced their collaboration to register and sell in Mexico a number of OTC and medical compounds from CURE which utilize CUREform™, CURE’s patented oral thin film (OTF) drug delivery platform. Cure is in talks with several major distributors in Mexico and Latin America.

OTF products that will be marketed and sold in Mexico through key distribution partners include:

CUREfilm Blue™ – an oral soluble form of sildenafil citrate (the active ingredient found in Viagra®1) for the treatment of erectile dysfunction (ED).Vitamin D3 – which provides a convenient weekly dose of 40,000 IU of the vitamin Energy-boosting electrolyte DAN – which offers a healthier, sugar-free alternative to energy drinks Sleep – a dose of melatonin that dissolves on the tongue so it can be taken even after you’ve gone to bed.

The opportunity to serve the Latin American market with this venture in Mexico is an exciting opportunity that should accelerate the ramp-up of CURE’s FDA-registered cGMP manufacturing facility, where the company launched and expanded its platform. patented CUREfilm™ drug delivery form. The Company plans to select a distribution partner for the LATAM territory in the coming months.

Martin Simon, CEO of Milagro Pharmaceuticals, said, “We are excited to be working with CURE to bring their innovative wellness products and proprietary drug forms and delivery systems to Mexico, with the intention of expanding our collaboration. to encompass the rest of Latin America where the demand for health and wellness products is growing faster than in many other parts of the world. »

About CURE Pharmaceutical CURE is the pioneer developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate and controlled release drug delivery vehicles designed to improve the efficacy, safety and patient experience for a wide range of active ingredients.

As a vertically integrated company, the 25,000 square foot, FDA and DEA registered, NSF® cGMP certified manufacturing facility allows it to partner with pharmaceutical and wellness companies around the world for private and white label production.

About Milagro Pharmaceuticals Milagro Pharmaceuticals is dedicated to the innovation, distribution and sale of a variety of disruptive technologies, all focused on healing people. The company’s growth has driven its recent expansion into Colombia, Canada and now Mexico.

About COFEPRIS COFEPRIS (the Federal Commission for the Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios) is the Mexican authority responsible for the application of the regulatory framework relating to medical products and is part of the Ministry of Health (Secretaria de Salud).

Forward-Looking Statements Statements made by CURE in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”). and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are generally identified by the use of words such as “anticipates”, “believes”, “estimates”, “s ‘expects’, ‘intends’, ‘may’, ‘plans’, ‘plans’, ‘seeks’, ‘should’, ‘will’ and variations of these words or similar expressions. CURE intends that such forward-looking statements are covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchanges Act and makes this statement in order to comply with these safe harbor provisions. Forward-looking statements contained in this press release reflect the judgment of CURE as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements.

1Viagra® is a registered trademark of Pfizer Inc.

Investor contacts:

Mike Redard [email protected]

Copyright 2022 GlobeNewswire, Inc.